MTAP deletion
Showing 1 - 25 of 198
Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
Completed
- Advanced Solid Tumors
- Lymphoma
-
Boston, Massachusetts
- +2 more
Mar 13, 2020
Esophageal Squamous Cell Carcinoma Trial (Combination (S095033 + paclitaxel))
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Combination (S095033 + paclitaxel)
- (no location specified)
Mar 28, 2022
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors Trial (AMG 193, IDE397)
Not yet recruiting
- MTAP-null Non-Small-Cell Lung Cancer
- MTAP-null Solid Tumors
- AMG 193
- IDE397
- (no location specified)
Jul 27, 2023
Advanced Solid Tumours That Are MTAP Deficient Trial in Spain, United States (AZD3470)
Not yet recruiting
- Advanced Solid Tumours That Are MTAP Deficient
-
New Haven, Connecticut
- +3 more
Nov 8, 2023
Advanced MTAP-null Solid Tumors Trial in Worldwide (AMG 193, Docetaxel)
Recruiting
- Advanced MTAP-null Solid Tumors
- AMG 193
- Docetaxel
-
Duarte, California
- +17 more
Aug 11, 2022
Photoaging Trial (In a double-blinded fashion, 250 mg CANNAXR cream, Topical VEHICLE cream)
Not yet recruiting
- Photoaging
- In a double-blinded fashion, 250 mg CANNAXR cream
- Topical VEHICLE cream
- (no location specified)
Aug 23, 2022
Urothelial Carcinoma, Metastatic Cancer Trial in Houston (Pemetrexed, Zimberelimab, Etrumadenant)
Not yet recruiting
- Urothelial Carcinoma
- Metastatic Cancer
- Pemetrexed
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Nov 28, 2022
Examining Genetic Factors That Affect Severity of 22q11.2
Recruiting
- DiGeorge Syndrome
- 22q11.2 Deletion Syndrome
-
New York, New York
- +1 more
Jul 18, 2022
NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Patritumab deruxtecan
- Osimertinib
-
Santa Monica, California
- +13 more
Feb 1, 2023
Angelman Syndrome Trial (60 mg QD Alogabat, 40 mg QD Alogabat, 7 mg QD Alogabat)
Not yet recruiting
- Angelman Syndrome
- 60 mg QD Alogabat
- +4 more
- (no location specified)
Feb 1, 2023
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular
Recruiting
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2021
Duchenne Muscular Dystrophy Trial in Worldwide (SRP-4045, SRP-4053, Placebo)
Active, not recruiting
- Duchenne Muscular Dystrophy
- SRP-4045
- +2 more
-
Phoenix, Arizona
- +74 more
Jan 17, 2023
Chronic Lymphocytic Leukemia Trial in Worldwide (Venetoclax)
Completed
- Chronic Lymphocytic Leukemia
-
Louisville, Kentucky
- +66 more
Nov 9, 2022
NSCLC Metastatic, NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Worldwide (Patritumab Deruxtecan (Fixed
Active, not recruiting
- Non-Small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Patritumab Deruxtecan (Fixed dose)
- Patritumab Deruxtecan (Up-Titration)
-
Gilbert, Arizona
- +120 more
Jan 12, 2023
Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Bortezomib)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
-
Salt Lake City, UtahHuntsman Cancer Institute/University of Utah
Sep 7, 2023
Non Small Cell Lung Cancer Trial in Seoul (Lazertinib+Pemetrexed+Carboplatin, Lazertinib)
Not yet recruiting
- Non Small Cell Lung Cancer
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Aug 31, 2023
Healthy Trial in Philadelphia (Blood draw)
Active, not recruiting
- Healthy
- Blood draw
-
Philadelphia, PennsylvaniaThe Clinical Translational Research Center (CTRC) at the Hospita
Aug 16, 2022
Partial PTEN Deletion in Breast Cancer
Not yet recruiting
- PTEN Gene Deletion
- (no location specified)
Oct 27, 2021
Glioma (Diagnosis), Liquid Biopsy, Deep Learning Trial in Wuhan, Nanchang (Prediction of glioma grading and molecular subtype)
Recruiting
- Glioma (Diagnosis)
- +2 more
- Prediction of glioma grading and molecular subtype
-
Wuhan, Hubei, China
- +1 more
Sep 8, 2022
Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)
Active, not recruiting
- Non Small Cell Lung Cancer Metastatic
-
Dublin, Ireland
- +24 more
Aug 23, 2022